Are chemokines essential or secondary participants in allergic responses?

Annals of Allergy, Asthma and Immunology

Volumn 84, Issue 6, 2000, Pages 569-581

  Gangur, Venugopal ^a   Oppenheim, Joost J ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Bldg 560 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 4; RANTES;

ALLERGIC REACTION; CHEMOTAXIS; DENDRITIC CELL; DRUG EFFECT; HISTAMINE RELEASE; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNE RESPONSE; MEDIATOR RELEASE; MEMBRANE BINDING; PRIORITY JOURNAL; REVIEW; TISSUE INJURY;

EID: 0033917908     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62403-9     Document Type: Review

References (105)

1. van Neerven RJ. The role of allergen-specific T cells in the allergic immune response: relevance to allergy vaccination. Allergy 1999;54:552-561.
2. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Ann Rev Immunol 1999;17: 255-281.
3. Erb KJ. Atopic disorders: a default pathway in the absence of infection? Immunol Today 1999;20(7):317-322.
4. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997;77(4): 1033-1079.
5. Kaplan AP, Kuna P, Reddigari SR. Chemokines and the allergic response. Exp Dermatol 1995;4(4 Pt 2): 260-265.
6. Alam R. Chemokines in allergic inflammation. J Allergy Clin Immunol 1997;99:273-277.
7. Kaplan AP, Kuna P. Chemokines and the late-phase reaction. Allergy 1998; 53(45 Suppl):27-32.
8. Romagnani P, De Paulis A, Beltrame C, et al. Tryptase-chymase double-positive human mast cells express the eotaxin receptor CCR3 and are attracted by CCR3-binding chemokines. Am J Pathol 1999;155:1195-1204.
9. Allavena P, Luini W, Bonecchi R, et al. Chemokines and chemokine receptors in the regulation of dendritic cell trafficking. Chem Immunol 1999;72: 69-85.
10. Dieu-Nosjean MC, Vicari A, Lebecque S, Caux C. Regulation of dendritic cell trafficking: a process that involves the participation of selective chemokines. J Leukoc Biol 1999;66: 252-262.
11. Zlotnik A, Morales J, Hedrick JA. Recent advances in chemokines and chemokine receptors. Crit Rev Immunol 1999;19:1-47.
12. Marone G. Asthma: recent advances [see comments]. Immunol Today 1998;19(1):5-9.
13. Bacon KB, Oppenheim JJ. Chemokines in disease models and pathogenesis. Cytokine Growth Factor Rev 1998;9(2):167-173.
14. Locati M, Murphy PM. Chemokines and chemokine receptors: biology and clinical relevance in inflammation and AIDS. Ann Rev Med 1999;50: 425-440.
15. Kimata H, Yoshida A, Ishioka C, et al. Interleukin 8 (IL-8) selectively inhibits immunoglobulin E production induced by IL-4 in human B cells. J Exp Med 1992;176:1227-1231.
16. Kimata H, Lindley I, Furusho K. Selective inhibition of spontaneous IgE and IgG4 production by interleukin-8 in atopic patients. Blood 1995;85: 3191-3198.
17. Kimata H, Yoshida A, Ishioka C, et al. RANTES and macrophage inflammatory protein 1 alpha selectively enhance immunoglobulin (IgE) and IgG4 production by human B cells. J Exp Med 1996;183:2397-2402.
18. Lukacs NW, Chensue SW, Karpus WJ, et al. C-C chemokines differentially alter interleukin-4 production from lymphocytes. Am J Pathol 1997;150: 1861-1868.
19. Devouassoux G, Metcalfe DD, Prussin C. Eotaxin potentiates antigen-dependent basophil IL-4 production. J Immunol 1999;163:2877-2882.
20. Baggiolini M, Dahinden CA. CC chemokines in allergic inflammation. Immunol Today 1994;15:127-133.
21. Gangur V, Simons FE, HayGlass KT. IP-10 mediated reinforcement of human type 1 cytokine synthesis to environmental allergens among non-atopic subjects. Int Arch Allergy Immunol 1999;118:387-390.
22. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Ann Rev Immunol 1997:675-705.
23. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338(7):436-445.
24. Kim CH, Broxmeyer HE. Chemokines: signal lamps for trafficking of T and B cells for development and effector function. J Leukoc Biol 1999;65:6-15.
25. Mantovani A. The chemokine system: redundancy for robust outputs. Immunol Today 1999;20:254-257.
26. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998;392:565-568.
27. Proudfoot AE. The chemokine family. Potential therapeutic targets from allergy to HIV infection. Eur J Dermatol 1998;8:147-157.
28. Leong SR, Lowman HB, Liu J, et al. IL-8 single-chain homodimers and heterodimers: interactions with chemokine receptors CXCR1, CXCR2, and DARC. Protein Sci 1997;6: 609-617.
29. Rajarathnam K, Sykes BD, Kay CM, et al. Neutrophil activation by monomeric interleukin-8. Science 1994;264: 90-92.
30. Lowman HB, Fairbrother WJ, Slagle PH, et al. Monomeric variants of IL-8: effects of side chain substitutions and solution conditions upon dimer formation. Protein Sci 1997;6:598-608.
31. Ben-Baruch A, Michiel DF, Oppenheim JJ. Signals and receptors involved in recruitment of inflammatory cells. J Biol Chem 1995;270: 11703-11706.
32. Ward SG, Bacon K, Westwick J. Chemokines and T lymphocytes: more than an attraction. Immunity 1998; 9(1):1-11.
33. Wong M, Fish EN. RANTES and MIP-1alpha activate stats in T cells. J Biol Chem 1998;273(1):309-314.
34. Gangur V, Simons FE, Hayglass KT. Human IP-10 selectively promotes dominance of polyclonally activated and environmental antigen-driven IFN-gamma over IL-4 responses. FASEB J 1998;12:705-713.
35. Terkeltaub R, Boisvert WA, Curtiss LK. Chemokines and atherosclerosis. Curr Opin Lipidol 1998;9:397-405.
36. Wang JM, Su S, Gong W, Oppenheim JJ. Chemokines, receptors, and their role in cardiovascular pathology. Int J Clin Lab Res 1998;28:83-90.
37. Tachibana K, Hirota S, Iizasa H, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract [see comments]. Nature 1998;393:591-594.
38. Zou YR, Kottmann AH, Kuroda M, et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development [see comments]. Nature 1998;393:595-599.
39. Minshall EM, Cameron L, Lavigne F, et al. Eotaxin mRNA and protein expression in chronic sinusitis and allergen-induced nasal responses in seasonal allergic rhinitis. Am J Respir Cell Mol Biol 1997;17:683-690.
40. Matthews AN, Friend DS, Zimmermann N, et al. Eotaxin is required for the baseline level of tissue eosinophils. Proc Natl Acad Sci U S A 1998;95: 6273-6278.
41. Santamaria Babi LF, Perez Soler MT, Hauser C, Blaser K. Skin-homing T cells in human cutaneous allergic inflammation. Immunol Res 1995;14(4): 317-324.
42. Beck LA, Dalke S, Leiferman KM, et al. Cutaneous injection of RANTES causes eosinophil recruitment: comparison of nonallergic and allergic human subjects. J Immunol 1997;159: 2962-2972.
43. Lamkhioued B, Renzi PM, Abi-Younes S, et al. Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation. J Immunol 1997; 159:4593-4601.
44. Ying S, Robinson DS, Meng Q, et al. C-C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other C-C chemokines (Monocyte chemoattractant protein-3 and RANTES). J Immunol 1999;163: 3976-3984.
45. MacLean JA, Ownbey R, Luster AD. T cell-dependent regulation of eotaxin in antigen-induced pulmonary eosinophilia. J Exp Med 1996;184: 1461-1469.
46. Ying S, Robinson DS, Meng Q, et al. Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur J Immunol 1997;27: 3507-3516.
47. Conti P, Reale M, Barbacane RC, et al. Intramuscular injection of hrRANTES causes mast cell recruitment and increased transcription of histidine decarboxylase in mice: lack of effects in genetically mast cell-deficient W?WV mice. FASEB J 1998;12:1693-1700.
48. Rothenberg ME, MacLean JA, Pearlman E, et al. Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. J Exp Med 1997;185:785-790.
49. Yang Y, Loy J, Ryseck RP, et al. Antigen-induced eosinophilic lung inflammation develops in mice deficient in chemokine eotaxin. Blood 1998;92: 3912-3923.
50. Heath H, Qin S, Rao P, et al. Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest 1997;99:178-184.
51. Corrigan CJ, Eotaxin and asthma: some answers, more questions. Clin Exp Immunol 1999;116:1-3.
52. Forssmann U, Uguccioni M, Loetscher P, et al. Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. J Exp Med 1997;185: 2171-2176.
53. Luster AD, Rothenberg ME. Role of the monocyte chemoattractant protein and eotaxin subfamily of chemokines in allergic inflammation. J Leukoc Biol 1997;62(5):620-633.
54. Shinkai A, Yoshisue H, Koike M, et al. A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophils. J Immunol 1999;163(3): 1602-1610.
55. Kitaura M, Suzuki N, Imai T, et al. Molecular cloning of a novel human CC chemokine (Eotaxin-3) that is a functional ligand of CC chemokine receptor 3. J Biol Chem 1999;274: 27975-27980.
56. Mould AW, Matthaei KI, Young IG, Foster PS. Relationship between interleukin-5 and eotaxin in regulating blood and tissue eosinophilia in mice. J Clin Invest 1997;99:1064-1071.
57. Rothenberg ME. Eotaxin. An essential mediator of eosinophil trafficking into mucosal tissues. Am J Respir Cell Mol Biol 1999;21:291-295.
58. Kaplan AP, Kuna P, Reddigari SR. Chemokines as allergic mediators -relationship to histamine-releasing factors. Allergy 1994;49:495-501.
59. Kuna P, Reddigari SR, Schall TJ, et al. Characterization of the human basophil response to cytokines, growth factors, and histamine releasing factors of the intercrine/chemokine family. J Immunol 1993;150:1932-1943.
60. Elsner J, Petering H, Kluthe C, et al. Eotaxin-2 activates chemotaxis-related events and release of reactive oxygen species via pertussis toxin-sensitive G proteins in human eosinophils. Eur J Immunol 1998;28:2152-2158.
61. El-Shazly A, Masuyama K, Nakano K, et al. Human eotaxin induces eosinophil-derived neurotoxin release from normal human eosinophils. Int Arch Allergy Immunol 1998;117 Suppl 1:55-58.
62. Mosmann TR, Sad S. The expanding universe of T cell subsets: Th1, Th2 and more. Immunol Today 1996;17: 138-146.
63. Morel PA, Oriss TB. Crossregulation between Th1 and Th2 cells. Crit Rev Immunol 1998;18:275-303.
64. Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997;18:263-266.
65. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-793.
66. Teran LM, Mochizuki M, Bartels J, et al. Th1- and Th2-type cytokines regulate the expression and production of eotaxin and RANTES by human lung fibroblasts. Am J Respir Cell Mol Biol 1999;20:777-786.
67. Mochizuki M, Bartels J, Mallet AI, et al. IL-4 induces eotaxin: a possible mechanism of selective eosinophil recruitment in helminth infection and atopy. J Immunol 1998;160:60-68.
68. Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999;103(6):779-788.
69. Li L, Xia Y, Nguyen A, et al. Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. J Immunol 1999;162: 2477-2487.
70. Miyamasu M, Yamaguchi M, Nakajima T, et al. Th1-derived cytokine IFN-gamma is a potent inhibitor of eotaxin synthesis in vitro. Int Immunol 1999;11:1001-1004.
71. Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, et al. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 1996;2:449-456.
72. Lilly CM, Nakamura H, Kesselman H, et al. Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids. J Clin Invest 1997;99:1767-1773.
73. Stellato C, Matsukura S, Fal A, et al. Differential regulation of epithelial-derived C-C chemokine expression by IL-4 and the glucocorticoid budesonide. J Immunol 1999;163(10): 5624-5632.
74. Andrew DP, Chang MS, McNinch J, et al. STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. J Immunol 1998;161:5027-5038.
75. D'Ambrosio D, Iellem A, Bonecchi R, et al. Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J Immunol 1998;161: 5111-5115.
76. Zingoni A, Soto H, Hedrick JA, et al. The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J Immunol 1998;161:547-551.
77. Karpus WJ, Kennedy KJ. MIP-1alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J Leukoc Biol 1997;62:681-687.
78. Karpus WJ, Lukacs NW, Kennedy KJ, et al. Differential CC chemokine-induced enhancement of T helper cell cytokine production. J Immunol 1997; 158:4129-4136.
79. Loetscher P, Uguccioni M, Bordoli L, et al. CCR5 is characteristic of Th1 lymphocytes. Nature 1998;391(6665): 344-345.
80. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/ Th2-mediated responses. Immunol Today 1998;19:568-574.
81. Sallusto F, Lenig D, Mackay CR, Lanzavecchia AM. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998;187: 875-883.
82. Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsi veness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998;187: 129-134.
83. Gao JL, Wynn TA, Chang Y, et al. Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor1. J Exp Med 1997;185:1959-1968.
84. Lu B, Rutledge BJ, Gu L, et al. Abnormalities in monoeyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med 1998;187:601-608.
85. Boring L, Gosling J, Chensue SW, et al. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest 1997; 100:2552-2561.
86. Zhou Y, Kurihara T, Ryseck RP, et al. Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J Immunol 1998;160: 4018-4025.
87. Spinozzi F, Agea E, Bistoni O, et al. Gamma delta T cells, allergen recognition and airway inflammation [see commente]. Immunol Today 1998;19:22-26.
88. Imada M, Simons FE, Jay FT, Hayglass KT. Allergen-stimulated interleukin-4 and interferon-gamma production in primary culture: responses of subjects with allergic rhinitis and normal controls. Immunology 1995; 85:373-380.
89. Li Y, Simons FE, Jay FT, HayGlass KT. Allergen-driven limiting dilution analysis of human IL-4 and IFN-gamma production in allergic rhinitis and clinically tolerant individuals. Int Immunol 1996; 8:897-904.
90. Holt PG. Mucosal immunity in relation to the development of oral tolerance/ sensitization. Allergy 1998;53(46 Suppl):16-19.
91. De Sanctis GT, MacLean JA, Qin S, et al. Interleukin-8 receptor modulates IgE production and B-cell expansion and trafficking in allergen-induced pulmonary inflammation. J Clin Invest 1999;103:507-515.
92. Baggiolini M. Eotaxin: a VIC (very important chemokine) of allergic inflammation? [editorial]. J Clin Invest 1996;97:587.
93. Griffiths-Johnson DA, Collins PD, Jose PJ, Williams TJ. Animal models of asthma: role of chemokines. Methods Enzymol 1997;288:241-266.
94. Proudfoot AE, Power CA, Hoogewerf AJ, et al. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 1996; 271(5):2599-2603.
95. Wells TN, Proudfoot AE. Chemokine receptors and their antagonists in allergic lung disease. Inflamm Res 1999; 48:353-362.
96. Gonzalo JA, Lloyd CM, Wen D, et al. The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J Exp Med 1998;188:157-167.
97. Elsner J, Petering H, Kimmig D, et al. The CC chemokine receptor antagonist met-RANTES inhibits eosinophil effector functions. Int Arch Allergy Immunol 1999;118:462-465.
98. Nibbs RJ, Salcedo TW, Campbell JD, et al. C-C chemokine receptor 3 antagonism by the beta-chemokine macrophage inflammatory protein 4, a property strongly enhanced by an amino-terminal alanine-methionine swap. J Immunol 2000;164(3):1488-1497.
99. Schols D, Struyf S, Van Damme J, et al. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997;186:1383-1388.
100. Schols D. Promising anti-HIV therapeutic strategy with a small molecule CXCR4 antagonist [In Process Citation]. Verh K Acad Geneeskd BeIg 1999;61:551-564.
101. Howard OM, Korte T, Tarasova NI, et al. Small molecule inhibitor of HIV-1 cell fusion blocks chemokine receptor-mediated function. J Leukoc Biol 1998;64:6-13.
102. Cookson W. The alliance of genes and environment in asthma and allergy. Nature 1999;402 (Suppl):B5-11.
103. Moffatt MF, Cookson WO. Genetics of asthma and inflammation: the status [In Process Citation]. Curr Opin Immunol 1999;11:606-609.
104. Locati M, Murphy PM. Chemokines and chemokine receptors: biology and clinical relevance in inflammation and AIDS. Annu Rev Med 1999; 50:425-440.
105. Soto H, Wang W, Strieter RM, et al. The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3. Proc Natl Acad Sci U S A 1998; 95(14):8205-8210.